title: [High-dose buprenorphine for outpatient palliative pain therapy].
abstract: The case of a 78-year-old patient with cancer-related pain and additionally mixed-pain syndrome is presented. Pain therapy with buprenorphine TTS 210 microg/h every 3 days was sufficient in the beginning, later the therapy was changed because of increasing problems of tape fixing during fever periods under chemotherapy to a continuous infusion of buprenorphine intravenously via an external medication pump. During the course of therapy it became necessary to increase the dose to 99.9 mg/day buprenorphine. Under this medication a sufficient pain reduction (median NRS 2-3) over a period of 135 days could be achieved. At the same time the patient was vigilant and cooperative without signs of intoxication until the end of life at home in the presence of his family.If no signs of intoxication occur under extreme opioid therapy and a sufficient pain therapy can be achieved, a rotation to another opioid is not necessary. However, outpatient palliative care requires a frequent adaptation to the individually varying opioid demand of the patient and time-consuming nursing care.
authors.affiliation: Schwerpunkt Krebsschmerztherapie, Zentrum für ambulantes Operieren und ambulante Schmerztherapie, Karl-Marx-Str. 42, 14482, Potsdam, Deutschland. knud.gastmeier@T-Online.de
authors.forename: K
authors.initials: K
authors.lastname: Gastmeier
authors.forename: E
authors.initials: E
authors.lastname: Freye
mesh_terms: D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D002047:Buprenorphine / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D015897:Comorbidity; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005266:Femoral Neoplasms / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D015918:Infusion Pumps, Implantable; D007902:Length of Stay; D008297:Male; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D010147:Pain Measurement / Q000187:drug effects; D010148:Intractable Pain / Q000188:drug therapy*; D010166:Palliative Care; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D002047:Buprenorphine